NYR :Improved Drug Candidate Selected for WRAIR Studies
• New lead drug candidate NYR-BI01 advances to efficacy studies in collaboration with the Walter Reed Army Institute of Research… Read more
Nyrada Receives A$1.0M R&D Tax Incentive Rebate
Cholesterol-Lowering Program Delivers Two New Potent Drug Candidates
Nyrada has this morning announced the commencement of new in vivo studies using the same mouse model as previously to… Read more
Nyrada Inc: Change of Registered Office and Principal Place of Business
Nyrada Receives Firm Commitments to Raise A$11 Million
Highlights: • Firm commitments received to raise A$11 million with strong demand from existing and new investors • Investment commitments… Read more
Nyrada Presentation March 2021- James Bonnar CEO
Nyrada Secures Collaboration with World-class Teams at Walter Reed & UNSW
• New collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) • World-leading scientific teams… Read more
